
    
The genomic variant c.4G>T p.Ala2Ser rs1208662086 is a missense mutation located in the SQSTM1 gene. SQSTM1 encodes for the protein sequestosome 1, which is also known as p62. This protein plays a crucial role in autophagy, a cellular process that degrades and recycles cellular components. Specifically, p62 serves as a cargo receptor that targets ubiquitinated proteins for degradation within the autophagosome, and it is also involved in signal transduction pathways related to inflammation and cell survival.The c.4G>T p.Ala2Ser variant results in the substitution of an alanine residue with a serine at the second position of the p62 protein. Although the papers provided do not directly discuss the functional consequences of this specific variant, they do provide insights into the broader functional context of the SQSTM1 gene and its protein product. For instance, p62/SQSTM1 is known to accumulate when autophagy is impaired, suggesting that mutations in SQSTM1 could potentially disrupt autophagy and lead to the accumulation of p62 and other autophagy substrates [2].Given the role of p62 in targeting ubiquitinated proteins for degradation, a missense mutation such as c.4G>T p.Ala2Ser could potentially alter the protein's ability to bind to ubiquitinated proteins or to autophagic machinery components, thereby affecting the efficiency of the autophagic process. However, without direct experimental evidence regarding the impact of the c.4G>T p.Ala2Ser variant on p62 function, the precise consequences of this mutation remain speculative.In summary, the SQSTM1 gene encodes for the p62 protein, which is integral to the autophagy pathway and cellular homeostasis. The c.4G>T p.Ala2Ser missense variant in SQSTM1 may affect the function of p62, potentially impacting the autophagic process and related cellular functions. Further experimental validation is required to determine the specific effects of this variant on protein function and its potential association with disease phenotypes.

ゲノム変異 c.4G>T p.Ala2Ser rs1208662086 は、SQSTM1遺伝子に位置するミスセンス変異です。SQSTM1は、セクエストソーム1（p62とも呼ばれる）というタンパク質をコードしています。このタンパク質は、細胞内の構成要素を分解・再利用するプロセスであるオートファジーにおいて重要な役割を果たします。具体的には、p62はユビキチン化されたタンパク質をオートファゴソーム内で分解するための貨物受容体として機能し、炎症や細胞生存に関連するシグナル伝達経路にも関与しています。

c.4G>T p.Ala2Ser変異は、p62タンパク質の2番目の位置にあるアラニン残基がセリンに置換される結果をもたらします。この特定の変異の機能的影響について直接議論している論文は提供されていませんが、SQSTM1遺伝子とそのタンパク質産物の広範な機能的背景についての洞察は示されています。例えば、p62/SQSTM1はオートファジーが障害されると蓄積することが知られており、SQSTM1の変異がオートファジーを妨げ、p62や他のオートファジー基質の蓄積を引き起こす可能性があることが示唆されています[2]。

ユビキチン化されたタンパク質を分解する役割を持つp62の機能を考えると、c.4G>T p.Ala2Serのようなミスセンス変異は、ユビキチン化されたタンパク質やオートファジー機構の構成要素への結合能力を変化させ、オートファジーの効率に影響を与える可能性があります。しかし、c.4G>T p.Ala2Ser変異がp62の機能に与える影響についての直接的な実験的証拠がないため、この変異の正確な結果は推測の域を出ません。

まとめると、SQSTM1遺伝子はオートファジー経路と細胞の恒常性に不可欠なp62タンパク質をコードしています。SQSTM1のc.4G>T p.Ala2Serミスセンス変異は、p62の機能に影響を与え、オートファジー過程や関連する細胞機能に影響を及ぼす可能性があります。この変異がタンパク質機能に与える具体的な影響や疾患表現型との関連を明らかにするためには、さらなる実験的検証が必要です。
    
## References
- [1] Paul S et al. (2024). "NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis." The Journal of cell biology, 223(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059900/)
- [2] Joffre C et al. (2015). "The Pro-apoptotic STK38 Kinase Is a New Beclin1 Partner Positively Regulating Autophagy." Current biology : CB, 25(19) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26387716/)
- [3] Liu S et al. (2018). "Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis." Cell death & disease, 9(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29686269/)
- [4] Castro-Gonzalez S et al. (2021). "HIV-1 Nef counteracts autophagy restriction by enhancing the association between BECN1 and its inhibitor BCL2 in a PRKN-dependent manner." Autophagy, 17(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32097085/)
- [5] Yeo SK et al. (2024). "AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer." Autophagy, 20(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/37733921/)
- [6] Iskandar K et al. (2024). "A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS." Autophagy, 20(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38261660/)
- [7] Zhang M et al. (2024). "USP20 deubiquitinates and stabilizes the reticulophagy receptor RETREG1/FAM134B to drive reticulophagy." Autophagy, 20(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38705724/)
- [8] Machtel R et al. (2024). "Late-onset Krabbe disease presenting as spastic paraplegia - implications of GCase and CTSB/D." Annals of clinical and translational neurology, 11(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38837642/)
- [9] Wang S et al. (2024). "NCAPH, ubiquitinated by TRIM21, promotes cell proliferation by inhibiting autophagy of cervical cancer through AKT/mTOR dependent signaling." Cell death & disease, 15(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39103348/)
- [10] Li Y et al. (2024). "Coronavirus M protein promotes mitophagy over virophagy by recruiting PDPK1 to phosphorylate SQSTM1 at T138." Nature communications, 15(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39414765/)
- [11] Dai S et al. (2017). "Methyl-beta-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK." Autophagy, 13(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28613987/)
- [12] Mitsui S et al. (2018). "Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model." Molecular brain, 11(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29843805/)
- [13] Wang S et al. (2020). "Overexpression of UBQLN1 reduces neuropathology in the P497S UBQLN2 mouse model of ALS/FTD." Acta neuropathologica communications, 8(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33028421/)
- [14] Nozaki M et al. (2021). "SQSTM1(L341V) variant that is linked to sporadic ALS exhibits impaired association with MAP1LC3 in cultured cells." eNeurologicalSci, 22() [PubMed](https://pubmed.ncbi.nlm.nih.gov/33319079/)
- [15] Li J et al. (2021). "Combination of autophagy and NFE2L2/NRF2 activation as a treatment approach for neuropathic pain." Autophagy, 17(12) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33834930/)

    
## ClinVar Submissions

    